Quick Answer
Annovis Bio, Inc. reported Earnings Per Share Diluted of $1.40 (loss) per share for the year ending 2025.
- Annovis Bio, Inc. showed an increase of +39.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Annovis Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $0.15 (loss) per share | Q1 2021: $0.46 (loss) per share | Q2 2021: $0.34 (loss) per share | Q3 2021: $0.35 (loss) per share | Q1 2022: $0.64 (loss) per share | Q2 2022: $0.73 (loss) per share | Q3 2022: $0.79 (loss) per share | Q1 2023: $1.07 (loss) per share | Q2 2023: $1.07 (loss) per share | Q3 2023: $1.63 (loss) per share | Q1 2024: $0.72 (loss) per share | Q2 2024: $0.44 (loss) per share | Q3 2024: $0.97 (loss) per share | Q1 2025: $0.32 (loss) per share | Q2 2025: $0.32 (loss) per share | Q3 2025: $0.37 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Annovis Bio, Inc.'s Earnings Per Share Diluted has declined by 60.9%.
- Historical annual values: Fiscal year 2025: $1.40 (loss) per share | Fiscal year 2024: $2.31 (loss) per share | Fiscal year 2023: $6.23 (loss) per share | Fiscal year 2022: $3.10 (loss) per share | Fiscal year 2021: $1.90 (loss) per share | Fiscal year 2020: $0.87 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: